Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10015121 | 0.93 | CHRM3 (1.00) | CHRM3 | |
| SCHEMBL13590238 | 0.93 | CHRM3 (0.87) | CHRM3 | |
| SCHEMBL274339 | 0.91 | CHRM3 (1.00) | CHRM3 | |
| SCHEMBL13590364 | 0.91 | CHRM3 (0.87) | CHRM3 | |
| SCHEMBL13590162 | 0.91 | CHRM3 (0.89) | CHRM3 | |
| SCHEMBL13590543 | 0.91 | CHRM3 (1.00) | CHRM3 | |
| SCHEMBL13590105 | 0.90 | CHRM3 (0.81) | CHRM3 | |
| SCHEMBL13590261 | 0.90 | CHRM3 (0.90) | CHRM3 | |
| SCHEMBL13590412 | 0.90 | CHRM3 (0.90) | CHRM3 | |
| SCHEMBL13590462 | 0.90 | CHRM3 (0.90) | CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682957-B2 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682957-B2 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-8754225-B2 | Process for preparing a biphenyl-2-ylcarbamic acid | THERAVANCE, INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754225-B2 | Process for preparing a biphenyl-2-ylcarbamic acid | THERAVANCE, INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-8138345-B2 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | THERAVANCE, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-7858797-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20100273755-A1 | DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-10-28 | — | — | US | disclosed |
| US-7560469-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-7265133-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-7265133-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2007-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273755-A1 | DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2A | CHRM3 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.